

ETRAVIRINE- etravirine tablet

AvKARE

HIGHLIGHTS OF PRESCRIBING INFORMATION

ETRAVIRINE tablets, for oral use

These highlights do not include all the information needed to use ETRAVIRINE TABLETS safely and effectively. See full prescribing information for ETRAVIRINE TABLETS.

Initial U.S. Approval: 2008

INDICATIONS AND USAGE

Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 2 years of age and older. (1) (1)

DOSAGE AND ADMINISTRATION

- Adult patients: 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. (2.1, 2.2, 2.4)
- Pregnant patients: 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. (2.2)
- Pediatric patients (2 years to less than 18 years of age and weighing at least 10 kg): dosage of etravirine tablets are based on body weight and should not exceed the recommended adult dose. Etravirine tablets should be taken following a meal. (2.3)

DOSAGE FORMS AND STRENGTHS

- Tablets: 25 mg, 100 mg, and 200 mg (3)

CONTRAINDICATIONS

None. (4)
(4)

WARNINGS AND PRECAUTIONS

- Severe, potentially life threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme. Immediately discontinue treatment if severe hypersensitivity, severe rash or rash with systemic symptoms or liver transaminase elevations develops and monitor clinical status, including liver transaminases closely. (5.1)
- Monitor for immune reconstitution syndrome and fat redistribution. (5.3, 5.4)

ADVERSE REACTIONS

The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy. (6.1)

The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Co-administration of etravirine with other drugs can alter the concentrations of other drugs and other drugs may alter the concentrations of etravirine. The potential drug-drug interactions must be considered prior to and during therapy. (7, 12.3)
(7)

USE IN SPECIFIC POPULATIONS

- Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dosage in Adult Patients
- 2.2 Recommended Dosage During Pregnancy
- 2.3 Recommended Dosage in Pediatric Patients (2 Years to Less Than 18 Years of Age)
- 2.4 Method of Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Severe Skin and Hypersensitivity Reactions
- 5.2 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions
- 5.3 Immune Reconstitution Syndrome
- 5.4 Fat Redistribution

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Potential for Other Drugs to Affect Etravirine
- 7.2 Potential for Etravirine to Affect Other Drugs
- 7.3 Significant Drug Interactions
- 7.4 Drugs Without Clinically Significant Interactions with Etravirine

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.4 Microbiology

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Treatment-Experienced Adult Subjects
- 14.2 Treatment-Experienced Pediatric Subjects (2 Years to Less Than 18 Years of Age)

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Etravirine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see *Microbiology (12.4)* and *Clinical Studies (14)*].

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage in Adult Patients

The recommended oral dosage of etravirine tablets for adult patients is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. The type of food does not affect the exposure to etravirine [see *Clinical Pharmacology (12.3)*].

2.2 Recommended Dosage During Pregnancy

The recommended oral dosage of etravirine tablets for pregnant individuals is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal [see *Use in Specific Populations (8.1)*].

2.3 Recommended Dosage in Pediatric Patients (2 Years to Less Than 18 Years of Age)

The recommended dosage of etravirine tablets for pediatric patients 2 years to less than 18 years of age and weighing at least 10 kg is based on body weight (see Table 1) not exceeding the recommended adult dosage. Etravirine tablets should be taken orally, following a meal. The type of food does not affect the exposure to etravirine tablets [see *Clinical Pharmacology (12.3)*].

Table 1: Recommended Dosage of Etravirine Tablets for Pediatric Patients 2 Years to Less Than 18 Years of Age

Body Weight kilograms (kg)	Dose
greater than or equal to 10 kg to less than 20 kg	100 mg twice daily
greater	

than or equal to 20 kg to less than 25 kg	125 mg twice daily
greater than or equal to 25 kg to less than 30 kg	150 mg twice daily
greater than or equal to 30 kg	200 mg twice daily

2.4 Method of Administration

Instruct patients to swallow the etravirine tablet(s) whole with liquid such as water. Patients who are unable to swallow the etravirine tablet(s) whole may disperse the tablet(s) in water. Instruct the patient to do the following:

- place the tablet(s) in 5 mL (1 teaspoon) of water, or at least enough liquid to cover the medication,
- stir well until the water looks milky,
- add approximately 15 mL (1 tablespoon) of liquid. Water may be used but other liquids, such as orange juice or milk, may improve taste. Patients should not place the tablets in orange juice or milk without first adding water. The use of warm (temperature greater than 104°F [greater than 40°C]) or carbonated beverages should be avoided.
- drink the mixture immediately,
- rinse the glass several times with orange juice, milk or water and completely swallow the rinse each time to make sure the patient takes the entire dose.

3 DOSAGE FORMS AND STRENGTHS

- 25 mg white to off-white, oval shaped, uncoated tablets debossed with “A56” on one side and score on the other side.
- 100 mg white to off-white oval shaped, uncoated tablets debossed with “AC75” on one side and plain on the other side.
- 200 mg white to off-white, oval shaped, uncoated tablets debossed with “AC76” on one side and plain on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Severe Skin and Hypersensitivity Reactions

Severe, potentially life-threatening and fatal skin reactions have been reported. In clinical trials, these include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. In Phase 3 clinical trials, Grade 3 and 4 rashes were reported in 1.3% of subjects receiving etravirine compared to 0.2% of placebo subjects. A total of 2.2% of HIV-1-infected subjects receiving etravirine discontinued from Phase 3 trials due to rash [see *Adverse Reactions (6.1)*]. Rash occurred most commonly during the first 6 weeks of therapy. The incidence of rash was higher in females [see *Adverse Reactions (6.1)*]. Stevens-Johnson syndrome was reported in 1.1% (2/177) of pediatric patients less than 18 years of age receiving etravirine in combination with other HIV-1 antiretroviral agents in an observational study.

Discontinue etravirine immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver transaminases should be monitored and appropriate therapy initiated. Delay in stopping etravirine treatment after the onset of severe rash may result in a life-threatening reaction.

5.2 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

The concomitant use of etravirine and other drugs may result in potentially significant drug interactions, some of which may lead to [see *Drug Interactions (7.3)*]:

- Loss of therapeutic effect of concomitant drug or etravirine and possible development of resistance.
- Possible clinically significant adverse reactions from greater exposures of etravirine or other concomitant drugs.

See Table 4 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during etravirine therapy and review concomitant medications during etravirine therapy.

5.3 Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including etravirine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

5.4 Fat Redistribution

Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

- Severe skin and hypersensitivity reactions [see *Warnings and Precautions (5.1)*].
- Immune reconstitution syndrome [see *Warnings and Precautions (5.3)*].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Adults

The safety assessment is based on all data from 1,203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received etravirine (200 mg twice daily). In these pooled trials, the median exposure for subjects in the etravirine arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the etravirine arm and 2.6% in the placebo arm.

The most frequently reported ADR at least Grade 2 in severity was rash (10.0%). Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with etravirine [see *Warnings and Precautions (5.1)*]. A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving etravirine discontinued due to rash. In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1 to 2 weeks on continued therapy. The incidence of rash was higher in women compared to men in the etravirine arm in the Phase 3 trials (rash \geq Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [see *Warnings and Precautions (5.1)*]. Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of etravirine-related rash compared to patients without a history of NNRTI-related rash.

Common Adverse Reactions

Clinical ADRs of moderate intensity or greater (greater than or equal to Grade 2) and reported in at least 2% of subjects treated with etravirine and occurring at a higher rate compared to placebo (excess of 1%) are presented in Table 2. Laboratory abnormalities considered ADRs are included in Table 3.

Table 2: Adverse Drug Reactions (Grades 2 to 4) in at Least 2% of Adult Subjects (Pooled TMC125-C206 and TMC125-C216 Trials)

Preferred Term	Etravirine + BR N=599 %	Placebo + BR N=604 %
Rash	10%	3%
Peripheral neuropathy	4%	2%
N=total number of subjects per treatment group; BR=background regimen		

Less Common Adverse Reactions

Treatment-emergent ADRs occurring in less than 2% of subjects (599 subjects) receiving etravirine and of at least moderate intensity (greater than or equal to Grade 2) are listed below by body system:

Cardiac Disorders: myocardial infarction, angina pectoris, atrial fibrillation

Ear and Labyrinth Disorders: vertigo

Eye Disorders: blurred vision

Gastrointestinal Disorders: gastroesophageal reflux disease, flatulence, gastritis, abdominal distension, pancreatitis, constipation, dry mouth, hematemesis, retching, stomatitis

General Disorders and Administration Site Conditions: sluggishness

Hematologic Disorders: hemolytic anemia

Hepatobiliary Disorders: hepatic failure, hepatomegaly, cytolytic hepatitis, hepatic steatosis, hepatitis

Immune System Disorders: drug hypersensitivity, immune reconstitution syndrome

Metabolism and Nutrition Disorders: diabetes mellitus, anorexia, dyslipidemia

Nervous System Disorders: paresthesia, somnolence, convulsion, hypoesthesia, amnesia, syncope, disturbance in attention, hypersomnia, tremor

Psychiatric Disorders: anxiety, sleep disorders, abnormal dreams, confusional state, disorientation, nervousness, nightmares

Renal and Urinary Disorders: acute renal failure

Reproductive System and Breast Disorders: gynecomastia

Respiratory, Thoracic and Mediastinal Disorders: exertional dyspnea, bronchospasm

Skin and Subcutaneous Tissue Disorders: night sweats, lipohypertrophy, prurigo, hyperhidrosis, dry skin, swelling face

Additional ADRs of at least moderate intensity observed in other trials were acquired lipodystrophy, angioneurotic edema, erythema multiforme and hemorrhagic stroke, each reported in no more than 0.5% of subjects.

Laboratory Abnormalities in Treatment-Experienced Patients

Selected Grade 2 to Grade 4 laboratory abnormalities that represent a worsening from baseline observed in adult subjects treated with etravirine are presented in Table 3.

Table 3: Selected Grade 2 to 4 Laboratory Abnormalities Observed in Treatment-Experienced Subjects (Pooled TMC125-C206 and TMC125-C216 Trials)

Laboratory Parameter	DAIDS Toxicity Range	Etravirine + BR N=599 %	Placebo + BR N=604 %
GENERAL BIOCHEMISTRY			
Pancreatic amylase			
Grade 2	> 1.5 to 2 x ULN	7%	8%
Grade 3	> 2 to 5 x ULN	7%	8%
Grade 4	> 5 x ULN	2%	1%
Lipase			
Grade 2	> 1.5 to 3 x ULN	4%	6%
Grade 3	> 3 to 5 x ULN	2%	2%
Grade 4	> 5 x ULN	1%	< 1%
Creatinine			
Grade 2	> 1.4 to 1.8 x ULN	6%	5%
Grade 3	> 1.9 to 3.4 x ULN	2%	1%
Grade 4	> 3.4 x ULN	0%	< 1%
HEMATOLOGY			
Decreased hemoglobin			
Grade 2	90 g/L to 99 g/L	2%	4%
Grade 3	70 g/L to 89 g/L	< 1%	< 1%
Grade 4	< 70 g/L	< 1%	< 1%
White blood cell count			
Grade 2	1,500 to 1,999/mm ³	2%	3%
	1,000 to		

Grade 3	1,499/mm ³	1%	4%
Grade 4	< 1,000/mm ³	1%	< 1%
Neutrophils			
Grade 2	750 to 999/mm ³	5%	6%
Grade 3	500 to 749/mm ³	4%	4%
Grade 4	< 500/mm ³	2%	3%
Platelet count			
Grade 2	50,000 to 99,999/mm ³	3%	5%
Grade 3	25,000 to 49,999/mm ³	1%	1%
Grade 4	< 25,000/mm ³	< 1%	< 1%
LIPIDS AND GLUCOSE			
Total cholesterol			
Grade 2	> 6.20 to 7.77 mmol/L 240 to 300 mg/dL	20%	17%
Grade 3	> 7.77 mmol/L > 300 mg/dL	8%	5%
Low density lipoprotein			
Grade 2	4.13 to 4.9 mmol/L 160 to 190 mg/dL	13%	12%
Grade 3	> 4.9 mmol/L > 190 mg/dL	7%	7%
Triglycerides			
	5.65 to 8.48		

Grade 2	mmol/L 500 to 750 mg/dL	9%	7%
Grade 3	8.49 to 13.56 mmol/L 751 to 1,200 mg/dL	6%	4%
Grade 4	> 13.56 mmol/L > 1200 mg/dL	4%	2%
Elevated glucose levels			
Grade 2	6.95 to 13.88 mmol/L 161 to 250 mg/dL	15%	13%
Grade 3	13.89 to 27.75 mmol/L 251 to 500 mg/dL	4%	2%
Grade 4	> 27.75 mmol/L > 500 mg/dL	0%	< 1%
HEPATIC PARAMETERS			
Alanine amino transferase			
Grade 2	2.6 to 5 x ULN	6%	5%
Grade 3	5.1 to 10 x ULN	3%	2%
Grade 4	> 10 x ULN	1%	< 1%
Aspartate amino transferase			
Grade 2	2.6 to 5 x ULN	6%	8%
Grade 3	5.1 to 10 x ULN	3%	2%
Grade 4	> 10 x	< 1%	< 1%

Grade 4	ULN	± 1/0	± 1/0
ULN=Upper Limit of Normal; BR=background regimen			

Patients Co-Infected With Hepatitis B and/or Hepatitis C Virus

In Phase 3 trials TMC125-C206 and TMC125-C216, 139 subjects (12.3%) with chronic hepatitis B and/or hepatitis C virus co-infection out of 1,129 subjects were permitted to enroll. AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups. Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of etravirine-treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected etravirine-treated subjects. In general, adverse events reported by etravirine-treated subjects with hepatitis B and/or hepatitis C virus co-infection were similar to etravirine-treated subjects without hepatitis B and/or hepatitis C virus co-infection.

Clinical Trials Experience in Pediatric Subjects (2 Years to Less Than 18 years of age)

The safety assessment in pediatric subjects is based on two single-arm trials. TMC125-C213 is a Phase 2 trial in which 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 6 years to less than 18 years of age received etravirine in combination with other antiretroviral agents (Week 24 analysis). TMC125-C234/IMPAACT P1090 is a Phase 1/2 trial in which 20 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 2 years to less than 6 years of age received etravirine in combination with other antiretroviral agents (Week 24 analysis) [see Clinical Studies (14.2)].

In TMC125-C213, the frequency, type and severity of adverse drug reactions in pediatric subjects 6 years to less than 18 years of age were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea. Rash was reported more frequently in female subjects than in male subjects (rash \geq Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males). Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects from 6 years to less than 18 years of age. In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was self-limiting and generally resolved within 1 week on continued therapy. The safety profile for subjects who completed 48 weeks of treatment was similar to the safety profile for subjects who completed 24 weeks of treatment.

In TMC125-C234/IMPAACT P1090, the frequency, type and severity of adverse drug reactions in pediatric subjects 2 years to less than 6 years of age through Week 24 were comparable to those observed in adults. The most common adverse drug reactions (any grade) of pediatric subjects were rash (50% [10/20]) and diarrhea (25% [5/20]). In this age group, no subjects had Grade 3 or Grade 4 rash and no subjects discontinued prematurely due to rash. One subject discontinued etravirine due to asymptomatic lipase elevation.

6.2 Postmarketing Experience

The following events have been identified during postmarketing use of etravirine.

Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [see *Warnings and Precautions (5.1)*].

Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis

Skin and Subcutaneous Tissue Disorders: Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported [see *Warnings and Precautions (5.1)*].

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect Etravirine

Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine (see Table 4) [see *Clinical Pharmacology (12.3)*].

7.2 Potential for Etravirine to Affect Other Drugs

Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-gp with etravirine may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s) (see Table 4) [see *Clinical Pharmacology (12.3)*].

7.3 Significant Drug Interactions

Table 4 shows significant drug interactions based on which, alterations in dose or regimen of etravirine and/or co-administered drug may be recommended. Drugs that are not recommended for co-administration with etravirine are also included in Table 4 [see *Clinical Pharmacology (12.3)*].

Table 4: Significant Drug Interactions

Concomitant Drug Class: Drug Name	Effect on Concentration of Etravirine or Concomitant Drug	Clinical Comment
HIV-antiviral agents: integrase strand inhibitors		
dolutegravir*	↓ dolutegravir ↔ etravirine	Etravirine significantly reduced plasma concentrations of dolutegravir. Using cross-study comparisons to historical pharmacokinetic data for etravirine, dolutegravir did not appear to affect

		the pharmacokinetics of etravirine.
dolutegravir/darunavir/ritonavir*	↓ dolutegravir ↔ etravirine	The effect of etravirine on dolutegravir plasma concentrations was mitigated by co-administration of darunavir/ritonavir or lopinavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir.
dolutegravir/lopinavir/ritonavir*	↔ dolutegravir ↔ etravirine	Dolutegravir should only be used with etravirine when co-administered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir.

HIV-antiviral agents: non-nucleoside reverse transcriptase inhibitors (NNRTIs)

efavirenz* nevirapine*	↓ etravirine	Combining two NNRTIs has not been shown to be beneficial. Concomitant use of etravirine with efavirenz or nevirapine may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and other NNRTIs is not recommended.
delavirdine	↑ etravirine	Combining two NNRTIs has not been shown to be beneficial. Etravirine and delavirdine should not be co-administered.
rilpivirine	↓ rilpivirine ↔ etravirine	Combining two NNRTIs has not been shown to be beneficial. Co-administration of etravirine and rilpivirine is not recommended.

HIV-antiviral agents: protease inhibitors (PIs)

atazanavir*	↓ atazanavir	Co-administration of etravirine and atazanavir without low dose
-------------	--------------	---

(without ritonavir)	↓ atazanavir	without low-dose ritonavir is not recommended.
atazanavir/ritonavir*	↓ atazanavir ↔ etravirine	Concomitant use of etravirine with atazanavir/ritonavir decreased atazanavir C _{min} but it is not considered clinically relevant. The mean systemic exposure (AUC) of etravirine after co-administration of etravirine with atazanavir/ritonavir in HIV-infected subjects was similar to the mean systemic exposure of etravirine observed in the Phase 3 trials after co-administration of etravirine and darunavir/ritonavir (as part of the background regimen). Etravirine and atazanavir/ritonavir can be co-administered without dose adjustments.
atazanavir/cobicistat	↓ atazanavir ↓ cobicistat	Co-administration of etravirine with atazanavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to atazanavir.
darunavir/ritonavir*	↓ etravirine	The mean systemic exposure (AUC) of etravirine was reduced when etravirine was co-administered with darunavir/ritonavir. Because all subjects in the Phase 3 trials received darunavir/ritonavir as part of the background regimen and etravirine exposures from these

		<p>trials were determined to be safe and effective, etravirine and darunavir/ritonavir can be co-administered without dose adjustments.</p>
darunavir/cobicistat	<p>↓ cobicistat darunavir: effect unknown</p>	<p>Co-administration of etravirine with darunavir/cobicistat is not recommended because it may result in loss of therapeutic effect and development of resistance to darunavir.</p>
fosamprenavir (without ritonavir)	<p>↑ amprenavir</p>	<p>Concomitant use of etravirine with fosamprenavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of amprenavir. Co-administration of etravirine and fosamprenavir without low-dose ritonavir is not recommended.</p>
fosamprenavir/ritonavir*	<p>↑ amprenavir</p>	<p>Due to a significant increase in the systemic exposure of amprenavir, the appropriate doses of the combination of etravirine and fosamprenavir/ritonavir have not been established. Co-administration of etravirine and fosamprenavir/ritonavir is not recommended.</p>
indinavir* (without ritonavir)	<p>↓ indinavir</p>	<p>Concomitant use of etravirine with indinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of indinavir. Co-administration of</p>

		etravirine and indinavir without low-dose ritonavir is not recommended.
lopinavir/ritonavir*	↓ etravirine	The mean systemic exposure (AUC) of etravirine was reduced after co-administration of etravirine with lopinavir/ritonavir (tablet). Because the reduction in the mean systemic exposures of etravirine in the presence of lopinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, etravirine and lopinavir/ritonavir can be co-administered without dose adjustments.
nelfinavir (without ritonavir)	↑ nelfinavir	Concomitant use of etravirine with nelfinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of nelfinavir. Co-administration of etravirine and nelfinavir without low-dose ritonavir is not recommended.
ritonavir*	↓ etravirine	Concomitant use of etravirine with ritonavir 600 mg twice daily may cause a significant decrease in the plasma concentration of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and ritonavir 600 mg twice daily is not recommended.

saquinavir/ritonavir*	↓ etravirine	The mean systemic exposure (AUC) of etravirine was reduced when etravirine was co-administered with saquinavir/ritonavir. Because the reduction in the mean systemic exposures of etravirine in the presence of saquinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, etravirine and saquinavir/ritonavir can be co-administered without dose adjustments.
tipranavir/ritonavir*	↓ etravirine	Concomitant use of etravirine with tipranavir/ritonavir may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of etravirine. Co-administration of etravirine and tipranavir/ritonavir is not recommended.
CCR5 antagonists		
maraviroc*	↔ etravirine ↓ maraviroc	When etravirine is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. No dose adjustment of etravirine is needed.
		When etravirine etravirine is co-administered with

maraviroc/darunavir/ritonavir* †	↔ etravirine ↑ maraviroc	maraviroc in the presence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 150 mg twice daily. No dose adjustment of etravirine is needed.
Other agents		
Antiarrhythmics: digoxin*	↔ etravirine ↑ digoxin	For patients who are initiating a combination of etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. For patients on a stable digoxin regimen and initiating etravirine, no dose adjustment of either etravirine or digoxin is needed. The serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.
amiodarone bepridil disopyramide flecainide lidocaine (systemic) mexiletine propafenone quinidine	↓ antiarrhythmics	Concentrations of these antiarrhythmics may be decreased when co-administered with etravirine. Etravirine and antiarrhythmics should be co-administered with caution. Drug concentration monitoring is recommended, if available.
Anticoagulant: warfarin	↑ anticoagulants	Warfarin concentrations may be increased when co-administered with etravirine. The international normalized ratio (INR) should be monitored when warfarin is combined with etravirine.

<p>Anticonvulsants: carbamazepine phenobarbital phenytoin</p>	<p>↓ etravirine</p>	<p>Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine.</p>
<p>Antifungals: fluconazole*</p>	<p>↑ etravirine ↔ fluconazole</p>	<p>Co-administration of etravirine and fluconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and fluconazole should be co-administered with caution. No dose adjustment of etravirine or fluconazole is needed.</p>
<p>voriconazole*</p>	<p>↑ voriconazole</p>	<p>Co-administration of etravirine and voriconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and voriconazole should be co-administered with caution. No dose adjustment of etravirine or voriconazole is needed.</p>
		<p>Posaconazole, a potent inhibitor of CYP3A4, may increase plasma concentrations of etravirine. Itraconazole</p>

<p>Antifungals: itraconazole ketoconazole posaconazole</p>	<p>↑ etravirine ↓ itraconazole ↓ ketoconazole ↔ posaconazole</p>	<p>and ketoconazole are potent inhibitors as well as substrates of CYP3A4. Concomitant systemic use of itraconazole or ketoconazole and etravirine may increase plasma concentrations of etravirine. Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by etravirine. Dose adjustments for itraconazole, ketoconazole or posaconazole may be necessary depending on the other co-administered drugs.</p>
<p>Antiinfective: clarithromycin*</p>	<p>↑ etravirine ↓ clarithromycin ↑ 14-OH-clarithromycin</p>	<p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-hydroxy-clarithromycin, were increased. Because 14-hydroxy-clarithromycin has reduced activity against <i>Mycobacterium avium</i> complex (MAC), overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC.</p>
<p>Antimalarial: artemether/lumefantrine*</p>	<p>↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine</p>	<p>Caution is warranted when co-administering etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite,</p>

	↓ intermediate	dihydroartemisinin, could result in decreased antimalarial efficacy. No dose adjustment is needed for etravirine.
Antimycobacterials: rifampin rifapentine	↓ etravirine	Rifampin and rifapentine are potent inducers of CYP450 enzymes. Etravirine should not be used with rifampin or rifapentine as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine.
Antimycobacterial: rifabutin*	↓ etravirine ↓ rifabutin ↓ 25- O- desacetyl-rifabutin	If etravirine is NOT co-administered with a protease inhibitor/ritonavir, then rifabutin at a dose of 300 mg once daily is recommended. If etravirine is co-administered with darunavir/ritonavir, lopinavir/ritonavir or saquinavir/ritonavir, then rifabutin should not be co-administered due to the potential for significant reductions in etravirine exposure.
Benzodiazepine: diazepam	↑ diazepam	Concomitant use of etravirine with diazepam may increase plasma concentrations of diazepam. A decrease in diazepam dose may be needed.
Corticosteroid: dexamethasone (systemic)	↓ etravirine	Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. This may result in loss of therapeutic effect of etravirine. Systemic dexamethasone should

		be used with caution or alternatives should be considered, particularly for long-term use.
Herbal products: St. John's wort (<i>Hypericum perforatum</i>)	↓ etravirine	Concomitant use of etravirine with products containing St. John's wort may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of etravirine. Etravirine and products containing St. John's wort should not be co-administered.
Hepatitis C virus (HCV) direct-acting antivirals: daclatasvir	↓ daclatasvir	Co-administration of etravirine with daclatasvir may decrease daclatasvir concentrations. Increase the daclatasvir dose to 90 mg once daily.
elbasvir/grazoprevir	↓ elbasvir ↓ grazoprevir	Co-administration of etravirine with elbasvir/grazoprevir may decrease elbasvir and grazoprevir concentrations, leading to reduced therapeutic effect of elbasvir/grazoprevir. Co-administration is not recommended.
simeprevir	↓ simeprevir	Co-administration of etravirine with simeprevir may decrease simeprevir concentrations. Co-administration is not recommended.
HMG-CoA reductase inhibitors: atorvastatin*	↔ etravirine ↓ atorvastatin ↑ 2-OH-atorvastatin	The combination of etravirine and atorvastatin can be given without dose adjustments, however, the dose of atorvastatin may need to be altered based on clinical response.
	↔ etravirine	No interaction between

pravastatin rosuvastatin	↔ etravirine ↔ pravastatin ↔ rosuvastatin	pravastatin, rosuvastatin and etravirine is expected.
lovastatin simvastatin	↓ lovastatin ↓ simvastatin	Lovastatin and simvastatin are CYP3A substrates and co-administration with etravirine may result in lower plasma concentrations of the HMG-CoA reductase inhibitor.
fluvastatin pitavastatin	↑ fluvastatin ↑ pitavastatin	Fluvastatin and pitavastatin are metabolized by CYP2C9 and co-administration with etravirine may result in higher plasma concentrations of the HMG-CoA reductase inhibitor. Dose adjustments for these HMG-CoA reductase inhibitors may be necessary.
Immunosuppressants: cyclosporine sirolimus tacrolimus	↓ immunosuppressant	Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected.
Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone* methadone*	↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone	Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone) maintenance therapy may need to be adjusted in some patients. Etravirine and methadone can be co-

		administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as methadone maintenance therapy may need to be adjusted in some patients.
Phosphodiesterase type 5 (PDE-5) inhibitors: sildenafil* tadalafil vardenafil	↓ sildenafil ↓ N-desmethyl-sildenafil	Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect.
Platelet aggregation inhibitors: clopidogrel	↓ clopidogrel (active) metabolite	Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with etravirine. Alternatives to clopidogrel should be considered.
<p>↑ = increase; ↓ = decrease; ↔ = no change * The interaction between etravirine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted. † The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir.</p>		

7.4 Drugs Without Clinically Significant Interactions with Etravirine

In addition to the drugs included in Table 4, the interaction between etravirine and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [see *Clinical Pharmacology (12.3)*]: didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to etravirine during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

Risk Summary

Prospective pregnancy data from clinical trials and the APR are not sufficient to adequately assess the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Etravirine use during pregnancy has been evaluated in a limited number of individuals as reported by the APR, and available data show 1 birth defect in 66 first trimester exposures to etravirine-containing regimens (*see Data*).

The estimated background rate for major birth defects is 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15% to 20%. The background risk of major birth defects and miscarriage for the indicated population is unknown.

In animal reproduction studies, no adverse developmental effects were observed with orally administered etravirine at exposures equivalent to those at the maximum recommended human dose (MRHD) of 400 mg daily (*see Data*).

Data

Human Data

Based on prospective reports to the APR of 116 live births following exposure to etravirine-containing regimens during pregnancy (including 66 exposed in the first trimester and 38 exposed in the second/third trimester), the number of birth defects in live births for etravirine was 1 out of 66 with first trimester exposure and 0 out of 38 with second/third trimester exposure. Prospective reports from the APR of overall major birth defects in pregnancies exposed to etravirine are compared with a U.S. background major birth defect rate. Methodological limitations of the APR include the use of MACDP as the external comparator group. Limitations of using an external comparator include differences in methodology and populations, as well as confounding due to the underlying disease; these limitations preclude an accurate comparison of outcomes.

Etravirine (200 mg twice daily) in combination with other antiretroviral agents was evaluated in a clinical trial enrolling 15 pregnant subjects during the second and third trimesters of pregnancy and postpartum. Thirteen subjects completed the trial through postpartum period (6 to 12 weeks after delivery). The pharmacokinetic data demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum [*see Clinical Pharmacology (12.3)*].

Among subjects who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) at baseline (9/13), virologic suppression was maintained through the third trimester and postpartum period. Among subjects with HIV-1 RNA greater than 50 copies/mL and less than 400 copies/mL at baseline (3/13), viral loads remained less than 400 copies/mL. In one subject with HIV-1 RNA greater than 1,000 copies/mL at baseline (1/13), HIV-1 RNA remained greater than 1,000 copies/mL during the study period. Thirteen infants were born to 13 HIV-infected pregnant individuals in this study. HIV-1 test results were not available for 2 infants. Among the eleven infants with HIV-1 test results available, who were born to 11 HIV-infected pregnant individuals who completed the study, all had test results that were negative for HIV-1 at the time of delivery. No unexpected safety findings were observed compared with the known safety profile of etravirine in non-pregnant adults.

Animal Data

Reproductive and developmental toxicity studies were performed in rats (at 250, 500 and 1,000 mg/kg/day) and rabbits (at 125, 250 and 375 mg/kg/day) administered etravirine on gestation days 6 through 16, and 6 through 19, respectively. In both species, no treatment-related embryo-fetal effects were observed. In addition, no treatment-related effects were observed in a pre- and postnatal development study performed in rats administered oral doses up to 500 mg/kg/day on gestation days 7 through lactation day 7. The systemic drug exposures achieved at the high dose in these animal studies were equivalent to those at the MRHD.

8.2 Lactation

Risk Summary

The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV.

Based on limited data, etravirine has been shown to be present in human breast milk. There are no data on the effects of etravirine on the breastfed infant, or the effects of etravirine on milk production.

Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants) and (3) adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed if they are receiving etravirine.

8.4 Pediatric Use

The safety and effectiveness of etravirine have been established for the treatment of HIV-infected pediatric patients from 2 years of age to less than 18 years [see *Indications and Usage (1)* and *Dosage and Administration (2.3)*]. Use of etravirine in pediatric patients 2 years to less than 18 years of age is supported by evidence from adequate and well-controlled studies of etravirine in adults with additional data from two Phase 2 trials in treatment-experienced pediatric subjects, TMC125-C213, 2 years to less than 18 years of age (N=101) and TMC125-C234/IMPAACT P1090, 2 years to less than 6 years of age (N = 20). Both studies were open-label, single arm trials of etravirine plus an optimized background regimen. In the clinical trials, the safety, pharmacokinetics, and efficacy were comparable to that observed in adults except for rash (greater than or equal to Grade 2) which was observed more frequently in pediatric subjects [see *Adverse Reactions (6.1)*, *Clinical Pharmacology (12.3)*, and *Clinical Studies (14.2)*]. Postmarketing reports of Stevens-Johnson syndrome in pediatric patients receiving etravirine have been reported [see *Warnings and Precautions (5.1)*, and *Adverse Reactions (6.2)*].

Treatment with etravirine is not recommended in pediatric patients less than 2 years of age [see *Clinical Pharmacology (12.3)*]. Five HIV-infected subjects from 1 year to < 2 years of age were enrolled in TMC125-C234/IMPAACT P1090. Etravirine exposure was lower than reported in HIV-infected adults (AUC_{12h} geometric mean ratio [90% CI] was 0.59 [0.34, 1.01] for pediatric subjects from 1 year to < 2 years of age compared to adults). Virologic failure at Week 24 (confirmed HIV-RNA greater than or equal to 400 copies/mL) occurred in 3 of 4 evaluable subjects who discontinued before or had reached Week 24. Genotypic and phenotypic resistance to etravirine developed in 1 of

the 3 subjects who experienced virologic failure.

8.5 Geriatric Use

Clinical studies of etravirine did not include sufficient numbers of subjects aged 65 years of age and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see *Clinical Pharmacology (12.3)*].

8.6 Hepatic Impairment

No dose adjustment of etravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. The pharmacokinetics of etravirine have not been evaluated in patients with severe hepatic impairment (Child-Pugh Class C) [see *Clinical Pharmacology (12.3)*].

8.7 Renal Impairment

Since the renal clearance of etravirine is negligible (less than 1.2%), a decrease in total body clearance is not expected in patients with renal impairment. No dose adjustments are required in patients with renal impairment. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis [see *Clinical Pharmacology (12.3)*].


10 OVERDOSAGE

There is no specific antidote for overdose with etravirine. Human experience of overdose with etravirine is limited. The highest dose studied in healthy volunteers was 400 mg once daily. Treatment of overdose with etravirine consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Because etravirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance.

11 DESCRIPTION

Etravirine, USP is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1).

The chemical name for etravirine is 4-[[6-amino-5-bromo-2-[(4-cyanophenyl) amino]-4-pyrimidinyl] oxy]-3,5-dimethylbenzotrile. Its molecular formula is C₂₀H₁₅BrN₆O and its molecular weight is 435.28 g/mol. Etravirine, USP has the following structural formula:



Etravirine, USP is a white to slightly yellowish-brown powder. Etravirine, USP is practically insoluble in water and freely soluble in some organic solvents like N,N-dimethylformamide and tetrahydrofuran.

Etravirine tablets, USP are for oral administration. Each etravirine tablet, USP contains 25 mg, 100 mg or 200 mg of etravirine, USP. It also contains the inactive ingredients: croscarmellose sodium, crospovidone (type A), colloidal silicon dioxide, hypromellose, low-substituted hydroxy propyl cellulose, magnesium stearate and microcrystalline cellulose.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Etravirine is an antiretroviral drug [see Microbiology (12.4)] .

12.2 Pharmacodynamics

Cardiac Electrophysiology

In a thorough QT/QTc study in 41 healthy subjects, etravirine 200 mg twice daily or 400 mg once daily did not affect the QT/QTc interval.

12.3 Pharmacokinetics

The pharmacokinetic properties of etravirine were determined in healthy adult subjects and in treatment-experienced HIV-1-infected adult and pediatric subjects. The systemic exposures (AUC) to etravirine were lower in HIV-1-infected subjects (Table 5) than in healthy subjects.

Table 5: Population Pharmacokinetic Estimates of Etravirine 200 mg Twice Daily in HIV-1-Infected Adult Subjects (Integrated Data from Phase 3 Trials at Week 48) *

Parameter	Etravirine N=575
AUC _{12h} (ng•h/mL)	

Geometric mean \pm standard deviation	4,522 \pm 4,710
Median (range)	4,380 (458 to 59,084)
C _{0h} (ng/mL)	
Geometric mean \pm standard deviation	297 \pm 391
Median (range)	298 (2 to 4,852)
* All HIV-1-infected subjects enrolled in Phase 3 clinical trials received darunavir/ritonavir 600/100 mg twice daily as part of their background regimen. Therefore, the pharmacokinetic parameter estimates shown in Table 5 account for reductions in the pharmacokinetic parameters of etravirine due to co-administration of etravirine with darunavir/ritonavir.	

Note: The median protein binding adjusted EC₅₀ for MT4 cells infected with HIV-1/IIIB *in vitro* equals 4 ng/mL.

Absorption and Bioavailability

Following oral administration, etravirine was absorbed with a T_{max} of about 2.5 to 4 hours. The absolute oral bioavailability of etravirine is unknown.

In healthy subjects, the absorption of etravirine is not affected by co-administration of oral ranitidine or omeprazole, drugs that increase gastric pH.

Effects of Food on Oral Absorption

The systemic exposure (AUC) to etravirine was decreased by about 50% when etravirine tablet was administered under fasting conditions, as compared to when etravirine tablet was administered following a meal. Within the range of meals studied, the systemic exposures to etravirine were similar. The total caloric content of the various meals

evaluated ranged from 345 kilocalories (17 grams fat) to 1,160 kilocalories (70 grams fat).

Distribution

Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) *in vitro*. The distribution of etravirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans.

Metabolism

In vitro experiments with human liver microsomes (HLMs) indicate that etravirine primarily undergoes metabolism by CYP3A, CYP2C9, and CYP2C19 enzymes. The major metabolites, formed by methyl hydroxylation of the dimethylbenzotrile moiety, were at least 90% less active than etravirine against wild-type HIV in cell culture.

Elimination

After single dose oral administration of 800 mg ¹⁴C-etravirine, 93.7% and 1.2% of the administered dose of ¹⁴C-etravirine was recovered in the feces and urine, respectively. Unchanged etravirine accounted for 81.2% to 86.4% of the administered dose in feces. Unchanged etravirine was not detected in urine. The mean (\pm standard deviation) terminal elimination half-life of etravirine was about 41 (\pm 20) hours.

Specific Populations

Geriatric Patients

Population pharmacokinetic analysis in HIV-infected subjects showed that etravirine pharmacokinetics are not considerably different within the age range (18 to 77 years) evaluated [see *Use in Specific Populations (8.5)*].

Pediatric Patients

The pharmacokinetics of etravirine in 115 treatment-experienced HIV-1-infected pediatric subjects, 2 years to less than 18 years of age showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving etravirine 200 mg twice daily [see *Dosage and Administration (2.3)*]. The pharmacokinetic parameters for etravirine (AUC_{12h} and C_{0h}) are summarized in Table 6.

Table 6: Pharmacokinetic Parameters for Etravirine in Treatment-Experienced HIV-1-Infected Pediatric Subjects 2 Years to Less Than 18 Years of Age (TMC125-C213 [Population PK]) and TMC125-C234/P1090)

Study	TMC125-C213	TMC125-C234/ IMPAACT P1090
Age Range (years)	(6 years to less than 18 years)	(2 years to less than 6 years)
Parameter	N = 101	N = 14
AUC _{12h} (ng•h/mL)		
Geometric mean ± standard deviation	3,742 ± 4,314	3504 ± 2923
Median (range)	4,499 (62 to 28,865)	3579 (1221 to 11815)
C _{0h} (ng/mL)		
Geometric mean ± standard deviation	205 ± 342	183 ± 240
Median (range)	287 (2 to 2,276)	162 (54 to 908)

The pharmacokinetics and dose of etravirine in pediatric subjects less than 2 years of age have not been established [see *Use in Specific Populations (8.4)*].

Additional pediatric use information is approved for Janssen Products, LP's INTELENCE[®] (etravirine) tablets. However, due to Janssen Products, LP's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Male and Female Patients

No significant pharmacokinetic differences have been observed between males and females.

Racial or Ethnic Groups

Population pharmacokinetic analysis of etravirine in HIV-infected subjects did not show an effect of race on exposure to etravirine.

Patients with Renal Impairment

The pharmacokinetics of etravirine have not been studied in patients with renal impairment. The results from a mass balance study with ¹⁴C-etravirine showed that less than 1.2% of the administered dose of etravirine is excreted in the urine as metabolites. No unchanged drug was detected in the urine. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis [see *Use in Specific Populations (8.7)*].

Patients with Hepatic Impairment

Etravirine is primarily metabolized by the liver. The steady-state pharmacokinetic parameters of etravirine were similar after multiple dose administration of etravirine to subjects with normal hepatic function (16 subjects), mild hepatic impairment (Child-Pugh Class A, 8 subjects), and moderate hepatic impairment (Child-Pugh Class B, 8 subjects). The effect of severe hepatic impairment on the pharmacokinetics of etravirine has not been evaluated [see *Use in Specific Populations (8.6)*].

Pregnancy and Postpartum

After intake of etravirine 200 mg twice daily in combination with other antiretroviral agents (13 subjects with 2 NRTIs, 1 subject with 2 NRTIs + lopinavir + ritonavir, 1 subject with 2 NRTIs + raltegravir), based on intra-individual comparison, the C_{max} and AUC_{12h} of total etravirine were 23% to 42% higher during pregnancy compared with postpartum (6 to 12 weeks). The C_{min} of total etravirine was 78 to 125% higher during pregnancy compared with postpartum (6 to 12 weeks), while two subjects had $C_{min} < 10$ ng/mL in the postpartum period (6 to 12 weeks) [C_{min} of total etravirine was 11% to 16% higher when these 2 subjects are excluded] (see Table 7) [see *Use in Specific Populations (8.1)*]. Increased etravirine exposures during pregnancy are not considered clinically significant. The protein binding of etravirine was similar (> 99%) during the second trimester, third trimester, and postpartum period.

Table 7: Pharmacokinetic Results of Total Etravirine After Administration of Etravirine 200 mg Twice Daily as Part of an Antiretroviral Regimen, During the 2nd Trimester of Pregnancy, the 3rd Trimester of Pregnancy, and Postpartum.

Parameter Mean ± SD (median)	Postpartum N=10	2nd Trimester N=13	3rd Trimester N=10*
C_{min} , ng/mL	269 ± 182 (284) †	383 ± 210 (346)	349 ± 103 (371)
C_{max} , ng/mL	569 ± 261 (528)	774 ± 300 (828)	785 ± 238 (694)
AUC_{12h} , ng•h/mL	5,004 ± 2521 (5,246)	6,617 ± 2766 (6,836)	6,846 ± 1482 (6,028)

*n=9 for AUC_{12h}

† Two subjects had $C_{min} < 10$ ng/mL, C_{min} was $334 ± 135$ (315) in the postpartum period when these subjects were excluded from the descriptive analysis (N=8).

Patients with Hepatitis B and/or Hepatitis C Virus Co-Infection

Population pharmacokinetic analysis of the TMC125-C206 and TMC125-C216 trials showed reduced clearance for etravirine in HIV-1-infected subjects with hepatitis B and/or C virus co-infection. Based upon the safety profile of etravirine [see *Adverse Reactions (6)*], no dose adjustment is necessary in patients co-infected with hepatitis B and/or C virus.

Drug Interactions

Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of etravirine with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine.

Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-gp. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-gp with etravirine may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s).

Drug interaction studies were performed with etravirine and other drugs likely to be co-administered and some drugs commonly used as probes for pharmacokinetic interactions. The effects of co-administration of other drugs on the AUC, C_{max}, and C_{min} values of etravirine are summarized in Table 8 (effect of other drugs on etravirine). The effect of co-administration of etravirine on the AUC, C_{max}, and C_{min} values of other drugs are summarized in Table 9 (effect of etravirine on other drugs). For information regarding clinical recommendations, [see *Drug Interactions (7)*].

Table 8: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs

Co-administered Drug	Dose/Schedule of Co-administered Drug	N	Exposure	Mean Ratio of Etravirine Pharmacokinetic Parameters 90% CI; No Effect = 1.00		
				C _{max}	AUC	C _{min}
Co-administration with HIV protease inhibitors (PIs)						
Atazanavir	400 mg once daily	14	↑	1.47 (1.36 to 1.59)	1.50 (1.41 to 1.59)	1.58 (1.46 to 1.70)
Atazanavir/ritonavir*	300 mg/100 mg once daily	14	↑	1.30 (1.17 to 1.44)	1.30 (1.18 to 1.44)	1.26 (1.12 to 1.42)
Darunavir/ritonavir	600 mg/100 mg twice daily	14	↓	0.68 (0.57 to 0.82)	0.63 (0.54 to 0.73)	0.51 (0.44 to 0.61)
Lopinavir/ritonavir (tablet)	400 mg/100 mg twice daily	16	↓	0.70 (0.64 to 0.78)	0.65 (0.59 to 0.71)	0.55 (0.49 to 0.62)
Ritonavir	600 mg twice daily	11	↓	0.68 (0.55 to 0.85)	0.54 (0.41 to 0.73)	N.A.

Saquinavir/ritonavir	1,000 mg/100 mg twice daily	14 ↓	0.63 (0.53 to 0.75)	0.67 (0.56 to 0.80)	0.71 (0.58 to 0.87)
Tipranavir/ritonavir	500 mg/200 mg twice daily	19 ↓	0.29 (0.22 to 0.40)	0.24 (0.18 to 0.33)	0.18 (0.13 to 0.25)
Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs)					
Didanosine	400 mg once daily	15 ↔	1.16 (1.02 to 1.32)	1.11 (0.99 to 1.25)	1.05 (0.93 to 1.18)
Tenofovir disoproxil fumarate	300 mg once daily	23 ↓	0.81 (0.75 to 0.88)	0.81 (0.75 to 0.88)	0.82 (0.73 to 0.91)
Co-administration with CCR5 antagonists					
Maraviroc	300 mg twice daily	14 ↔	1.05 (0.95 to 1.17)	1.06 (0.99 to 1.14)	1.08 (0.98 to 1.19)
Maraviroc (when co-administered with darunavir/ritonavir) †	150 mg/600 mg/100 mg twice daily	10 ↔	1.08 (0.98 to 1.20)	1.00 (0.86 to 1.15)	0.81 (0.65 to 1.01)
Co-administration with integrase strand transfer inhibitors					
Raltegravir	400 mg twice daily	19 ↔	1.04 (0.97 to 1.12)	1.10 (1.03 to 1.16)	1.17 (1.10 to 1.26)
Co-administration with other drugs					
Artemether/lumefantrine	80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours	14 ↔	1.11 (1.06 to 1.17)	1.10 (1.06 to 1.15)	1.08 (1.04 to 1.14)
Atorvastatin	40 mg once daily	16 ↔	0.97 (0.93 to 1.02)	1.02 (0.97 to 1.07)	1.10 (1.02 to 1.19)
Clarithromycin	500 mg twice daily	15 ↑	1.46 (1.38 to 1.56)	1.42 (1.34 to 1.50)	1.46 (1.36 to 1.58)
Fluconazole	200 mg once daily in the morning	16 ↑	1.75 (1.60 to 1.91)	1.86 (1.73 to 2.00)	2.09 (1.90 to 2.31)

Omeprazole	40 mg once daily	18 ↑	1.17 (0.96 to 1.43)	1.41 (1.22 to 1.62)	N.A.
Paroxetine	20 mg once daily	16 ↔	1.05 (0.96 to 1.15)	1.01 (0.93 to 1.10)	1.07 (0.98 to 1.17)
Ranitidine	150 mg twice daily	18 ↓	0.94 (0.75 to 1.17)	0.86 (0.76 to 0.97)	N.A.
Rifabutin	300 mg once daily	12 ↓	0.63 (0.53 to 0.74)	0.63 (0.54 to 0.74)	0.65 (0.56 to 0.74)
Voriconazole	200 mg twice daily	16 ↑	1.26 (1.16 to 1.38)	1.36 (1.25 to 1.47)	1.52 (1.41 to 1.64)

CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change

* The systemic exposure of etravirine when co-administered with atazanavir/ritonavir in HIV infected subjects is similar to exposures of etravirine observed in the Phase 3 trials after co-administration of etravirine and darunavir/ritonavir (as part of the background regimen).

† The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir.

Table 9: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Etravirine

Co-administered Drug	Dose/Schedule of Co-administered Drug	N	Exposure	Mean Ratio of Co-administered Drug Pharmacokinetic Parameters 90% CI; No effect = 1.00		
				C _{max}	AUC	C _{min}
Co-administration with HIV protease inhibitors (PIs)						
Atazanavir	400 mg once daily	14	↓	0.97 (0.73 to 1.29)	0.83 (0.63 to 1.09)	0.53 (0.38 to 0.73)
Atazanavir/ritonavir	300 mg/100 mg once daily	13	↓	0.97 (0.89	0.86 (0.79	0.62 (0.55

Atazanavir/ritonavir	300 mg/100 mg once daily	15 ↓		to 1.05)	to 0.93)	to 0.71)
Atazanavir/ritonavir*	300 mg/100 mg once daily	20 ↓		0.96 (0.80 to 1.16)	0.96 (0.76 to 1.22)	0.82 (0.55 to 1.22)
Darunavir/ritonavir	600 mg/100 mg twice daily	15 ↔		1.11 (1.01 to 1.22)	1.15 (1.05 to 1.26)	1.02 (0.90 to 1.17)
Fosamprenavir/ritonavir	700 mg/100 mg twice daily	8 ↑		1.62 (1.47 to 1.79)	1.69 (1.53 to 1.86)	1.77 (1.39 to 2.25)
Lopinavir/ritonavir (tablet)	400 mg/100 mg twice daily	16 ↔		0.89 (0.82 to 0.96)	0.87 (0.83 to 0.92)	0.80 (0.73 to 0.88)
Saquinavir/ritonavir	1,000 mg/100 mg twice daily	15 ↔		1.00 (0.70 to 1.42)	0.95 (0.64 to 1.42)	0.80 (0.46 to 1.38)
Tipranavir/ritonavir	500 mg/200 mg twice daily	19 ↑		1.14 (1.02 to 1.27)	1.18 (1.03 to 1.36)	1.24 (0.96 to 1.59)
Co-administration with nucleoside reverse transcriptase inhibitors (NRTIs)						
Didanosine	400 mg once daily	14 ↔		0.91 (0.58 to 1.42)	0.99 (0.79 to 1.25)	N.A.
Tenofovir disoproxil fumarate	300 mg once daily	19 ↔		1.15 (1.04 to 1.27)	1.15 (1.09 to 1.21)	1.19 (1.13 to 1.26)
Co-administration with CCR5 antagonists						
Maraviroc	300 mg twice daily	14 ↓		0.40 (0.28 to 0.57)	0.47 (0.38 to 0.58)	0.61 (0.53 to 0.71)
Maraviroc (when co- administered with darunavir/ritonavir) †	150 mg/600 mg/100 mg twice daily	10 ↑		1.77 (1.20 to 2.60)	3.10 (2.57 to 3.74)	5.27 (4.51 to 6.15)
Co-administration with integrase strand transfer inhibitors						
Dolutegravir	50 mg once daily	16 ↓		0.48 (0.43 to 0.54)	0.29 (0.26 to 0.34)	0.12 (0.09 to 0.16)

Dolutegravir (when co-administered with darunavir/ritonavir)	50 mg once daily + 600/100 mg twice daily	9	↓	0.88 (0.78 to 1.00)	0.75 (0.69 to 0.81)	0.63 (0.52 to 0.76)
Dolutegravir (when co-administered with lopinavir/ritonavir)	50 mg once daily + 400/100 mg twice daily	8	↔	1.07 (1.02 to 1.13)	1.11 (1.02 to 1.20)	1.28 (1.13 to 1.45)
Raltegravir	400 mg twice daily	19	↓	0.89 (0.68 to 1.15)	0.90 (0.68 to 1.18)	0.66 (0.34 to 1.26)
Co-administration with other drugs						
Artemether	80 mg/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours	15	↓	0.72 (0.55 to 0.94)	0.62 (0.48 to 0.80)	0.82 (0.67 to 1.01)
Dihydroartemisinin		15	↓	0.84 (0.71 to 0.99)	0.85 (0.75 to 0.97)	0.83 (0.71 to 0.97)
Lumefantrine		15	↓	1.07 (0.94 to 1.23)	0.87 (0.77 to 0.98)	0.97 (0.83 to 1.15)
Atorvastatin	40 mg once daily	16	↓	1.04 (0.84 to 1.30)	0.63 (0.58 to 0.68)	N.A.
2-hydroxy-atorvastatin		16	↑	1.76 (1.60 to 1.94)	1.27 (1.19 to 1.36)	N.A.
Buprenorphine	Individual dose regimen ranging from 4/1 mg to 16/4 mg once daily	16	↓	0.89 (0.76 to 1.05)	0.75 (0.66 to 0.84)	0.60 (0.52 to 0.68)
Norbuprenorphine		16	↔	1.08 (0.95 to 1.23)	0.88 (0.81 to 0.96)	0.76 (0.67 to 0.87)
Clarithromycin	500 mg twice daily	15	↓	0.66 (0.57 to 0.77)	0.61 (0.53 to 0.69)	0.47 (0.38 to 0.57)
14-hydroxy-clarithromycin		15	↑	1.33 (1.13 to 1.56)	1.21 (1.05 to 1.39)	1.05 (0.90 to 1.22)

Digoxin	0.5 mg single-dose	16 ↑	1.19 (0.96 to 1.49)	1.18 (0.90 to 1.56)	N.A.
Ethinylestradiol	0.035 mg once daily	16 ↑	1.33 (1.21 to 1.46)	1.22 (1.13 to 1.31)	1.09 (1.01 to 1.18)
Norethindrone	1 mg once daily	16 ↔	1.05 (0.98 to 1.12)	0.95 (0.90 to 0.99)	0.78 (0.68 to 0.90)
Fluconazole	200 mg once daily in the morning	15 ↔	0.92 (0.85 to 1.00)	0.94 (0.88 to 1.01)	0.91 (0.84 to 0.98)
R(-) Methadone	Individual dose regimen ranging from 60 to 130 mg/day	16 ↔	1.02 (0.96 to 1.09)	1.06 (0.99 to 1.13)	1.10 (1.02 to 1.19)
S(+) Methadone		16 ↔	0.89 (0.83 to 0.97)	0.89 (0.82 to 0.96)	0.89 (0.81 to 0.98)
Paroxetine	20 mg once daily	16 ↔	1.06 (0.95 to 1.20)	1.03 (0.90 to 1.18)	0.87 (0.75 to 1.02)
Rifabutin	300 mg once daily	12 ↓	0.90 (0.78 to 1.03)	0.83 (0.75 to 0.94)	0.76 (0.66 to 0.87)
25- O-desacetyl-rifabutin	300 mg once daily	12 ↓	0.85 (0.72 to 1.00)	0.83 (0.74 to 0.92)	0.78 (0.70 to 0.87)
Sildenafil	50 mg single-dose	15 ↓	0.55 (0.40 to 0.75)	0.43 (0.36 to 0.51)	N.A.
N-desmethyl-sildenafil		15 ↓	0.75 (0.59 to 0.96)	0.59 (0.52 to 0.68)	N.A.
Voriconazole	200 mg twice daily	14 ↑	0.95 (0.75 to 1.21)	1.14 (0.88 to 1.47)	1.23 (0.87 to 1.75)

CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ =

increase; ↓ = decrease; ↔ = no change
* HIV-infected subjects
† compared to maraviroc 150 mg twice daily

12.4 Microbiology

Mechanism of Action

Etravirine is an NNRTI of HIV-1. Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases α , β , and γ .

Antiviral Activity in Cell Culture

Etravirine exhibited activity against laboratory strains and clinical isolates of wild-type HIV-1 in acutely infected T-cell lines, human peripheral blood mononuclear cells, and human monocytes/macrophages with median EC₅₀ values ranging from 0.9 nM to 5.5 nM (i.e. 0.4 ng/mL to 2.4 ng/mL). Etravirine demonstrated antiviral activity in cell culture against a broad panel of HIV-1 group M isolates (subtype A, B, C, D, E, F, G) with EC₅₀ values ranging from 0.29 nM to 1.65 nM and EC₅₀ values ranging from 11.5 nM to 21.7 nM against group O primary isolates. Etravirine did not show antagonism when studied in combination with the following antiretroviral drugs—the NNRTIs delavirdine, efavirenz, and nevirapine; the N(t)RTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zidovudine; the PIs amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir; the gp41 fusion inhibitor ENF; the integrase strand transfer inhibitor raltegravir and the CCR5 co-receptor antagonist maraviroc.

Resistance

In Cell Culture

Etravirine-resistant strains were selected in cell culture originating from wild-type HIV-1 of different origins and subtypes, as well as NNRTI resistant HIV-1. Development of reduced susceptibility to etravirine typically required more than one substitution in reverse transcriptase of which the following were observed most frequently: L100I, E138K, E138G, V179I, Y181C, and M230I.

In Treatment-Experienced Subjects

In the Phase 3 trials TMC125-C206 and TMC125-C216, substitutions that developed most commonly in subjects with virologic failure at Week 48 to the etravirine-containing regimen were V179F, V179I, and Y181C which usually emerged in a background of multiple other NNRTI resistance-associated substitutions. In all the trials conducted with etravirine in HIV-1 infected subjects, the following substitutions emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y. Other NNRTI-resistance-associated substitutions which emerged on etravirine treatment in less than 10% of the virologic failure isolates included K101E/H/P, K103N/R, V106I/M, V108I, Y181I, Y188L, V189I, G190S/C, N348I and R356K. The emergence of NNRTI substitutions on etravirine treatment contributed to decreased susceptibility to etravirine with a median fold-change in etravirine susceptibility of 40-fold from reference and a median fold-change of 6-fold from baseline.

Cross-Resistance

Cross-resistance among NNRTIs has been observed. Cross-resistance to delavirdine, efavirenz, and/or nevirapine is expected after virologic failure with an etravirine-containing regimen. Virologic failure on a rilpivirine-containing regimen with development of rilpivirine resistance is likely to result in cross-resistance to etravirine (see *Treatment-Naïve HIV-1-Infected Subjects in the Phase 3 Trials for EDURANT (rilpivirine)* below). Cross-resistance to etravirine has been observed after virologic failure on a doravirine-containing regimen with development of doravirine resistance. Some NNRTI-resistant viruses are susceptible to etravirine, but genotypic and phenotypic testing should guide the use of etravirine (see Baseline Genotype/Phenotype and Virologic Outcome Analyses below).

Site-Directed NNRTI Mutant Virus

Etravirine showed antiviral activity against 55 of 65 HIV-1 strains (85%) with single amino acid substitutions at RT positions associated with NNRTI resistance, including the most commonly found K103N. The single amino acid substitutions associated with an etravirine reduction in susceptibility greater than 3-fold were K101A, K101P, K101Q, E138G, E138Q, Y181C, Y181I, Y181T, Y181V, and M230L, and of these, the greatest reductions were Y181I (13-fold change in EC₅₀ value) and Y181V (17-fold change in EC₅₀ value). Mutant strains containing a single NNRTI resistance-associated substitution (K101P, K101Q, E138Q, or M230L) had cross-resistance between etravirine and efavirenz.

The majority (39 of 61; 64%) of the NNRTI mutant viruses with 2 or 3 amino acid substitutions associated with NNRTI resistance had decreased susceptibility to etravirine (fold-change greater than 3). The highest levels of resistance to etravirine were observed for HIV-1 harboring a combination of substitutions V179F + Y181C (187 fold-change), V179F + Y181I (123 fold-change), or V179F + Y181C + F227C (888 fold-change).

Clinical Isolates

Etravirine retained a fold-change less than or equal to 3 against 60% of 6171 NNRTI-resistant clinical isolates. In the same panel, the proportion of clinical isolates resistant to delavirdine, efavirenz and/or nevirapine (defined as a fold-change above their respective biological cutoff values in the assay) was 79%, 87%, and 95%, respectively. In TMC125-C206 and TMC125-C216, 34% of the baseline isolates had decreased susceptibility to etravirine (fold-change greater than 3) and 60%, 69%, and 78% of all baseline isolates were resistant to delavirdine, efavirenz, and nevirapine, respectively. Of subjects who received etravirine and were virologic failures in TMC125-C206 and TMC125-C216, 90%, 84%, and 96% of viral isolates obtained at the time of treatment failure were resistant to delavirdine, efavirenz, and nevirapine, respectively.

Treatment-Naïve HIV-1-Infected Subjects in the Phase 3 Trials for EDURANT (Rilpivirine)

There are currently no clinical data available on the use of etravirine in subjects who experienced virologic failure on a rilpivirine-containing regimen. However, in the rilpivirine adult clinical development program, there was evidence of phenotypic cross-resistance between rilpivirine and etravirine. In the pooled analyses of the Phase 3 clinical trials for rilpivirine, 38 rilpivirine virologic failure subjects had evidence of HIV-1 strains with genotypic and phenotypic resistance to rilpivirine. Of these subjects, 89% (34 subjects) of virologic failure isolates were cross-resistant to etravirine based on phenotype data.

Consequently, it can be inferred that cross-resistance to etravirine is likely after virologic failure and development of rilpivirine resistance. Refer to the prescribing information for EDURANT (rilpivirine) for further information.

Baseline Genotype/Phenotype and Virologic Outcome Analyses

In TMC125-C206 and TMC125-C216, the presence at baseline of the substitutions L100I, E138A, I167V, V179D, V179F, Y181I, Y181V, or G190S was associated with a decreased virologic response to etravirine. Additional substitutions associated with a decreased virologic response to etravirine when in the presence of 3 or more additional 2008 IAS-USA defined NNRTI substitutions include A98G, K101H, K103R, V106I, V179T, and Y181C. The presence of K103N, which was the most prevalent NNRTI substitution in TMC125-C206 and TMC125-C216 at baseline, did not affect the response in the etravirine arm. Overall, response rates to etravirine decreased as the number of baseline NNRTI substitutions increased (shown as the proportion of subjects achieving viral load less than 50 plasma HIV RNA copies/mL at Week 48) (Table 10).

Table 10: Proportion of Subjects With Less Than 50 HIV-1 RNA Copies/mL at Week 48 by Baseline Number of IAS-USA-Defined NNRTI Substitutions* in the Non-VF Excluded Population of the Pooled TMC125-C206 and TMC125-C216

# IAS-USA-Defined NNRTI substitutions*	Etravirine N=561	
	Re-used/not used ENF	de novo ENF
All ranges	61% (254/418)	76% (109/143)
0	68% (52/76)	95% (20/21)
1	67% (72/107)	77% (24/31)
2	64% (75/118)	86% (38/44)
3	55% (36/65)	62% (16/26)
≥ 4	37% (19/52)	52% (11/21)
	Placebo N=592	
All ranges	34% (147/435)	59% (93/157)
ENF: enfuvirtide		
* 2008 IAS-USA defined substitutions = V90I, A98G, L100I, K101E/H/P, K103N, V106A/I/M, V108I, E138A, V179D/F/T, Y181C/I/V, Y188C/H/L, G190A/S, P225H, M230L		

Response rates assessed by baseline etravirine phenotype are shown in Table 11. These baseline phenotype groups are based on the select subject populations in TMC125-C206 and TMC125-C216 and are not meant to represent definitive clinical susceptibility breakpoints for etravirine. The data are provided to give clinicians information on the likelihood of virologic success based on pre-treatment susceptibility to etravirine in treatment-experienced patients.

Table 11: Proportion of Subjects With Less Than 50 HIV-1 RNA Copies/mL at Week 48 by Baseline Phenotype and ENF Use in the Pooled TMC125-C206 and TMC125-C216*

Fold Change	Etravirine N=559		
	Re-used/not used ENF	de novo ENF	Clinical response range
All ranges	61% (253/416)	76% (109/143)	Overall Response
0 to 3	69% (188/274)	83% (75/90)	Higher than Overall Response
> 3 to 13	50% (39/78)	66% (25/38)	Lower than Overall Response
> 13	41% (26/64)	60% (9/15)	Lower than Overall Response
	Placebo N=583		
All ranges	34% (145/429)	60% (92/154)	

ENF: enfuvirtide
* Non-VF excluded analysis

The proportion of virologic responders (viral load less than 50 HIV-1 RNA copies/mL) by the phenotypic susceptibility score (PSS) of the background therapy, including ENF, is shown in Table 12.

Table 12: Virologic Response (Viral Load Less Than 50 HIV-1 RNA Copies/mL) at Week 48 by Phenotypic Susceptibility Score (PSS) in the Non-VF Excluded Population of TMC125-C206 and TMC125-C216

PSS*	Etravirine + BR N=559	Placebo + BR N=586
0	43% (40/93)	5% (5/95)
1	61% (125/206)	28% (64/226)
2	77% (114/149)	59% (97/165)
≥ 3	75% (83/111)	72% (72/100)

* The phenotypic susceptibility score (PSS) was defined as the total number of active antiretroviral drugs in the background therapy to which a subject's baseline viral isolate showed sensitivity in phenotypic resistance tests. Each drug in the background therapy was scored as a '1' or '0' based on whether the viral isolate was considered susceptible

or resistant to that drug, respectively. In the calculation of the PSS, darunavir was counted as a sensitive antiretroviral if the FC was less than or equal to 10; ENF was counted as a sensitive antiretroviral if it had not been used previously. Etravirine was not included in this calculation.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Etravirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to approximately 104 weeks. Daily doses of 50 mg/kg, 200 mg/kg and 400 mg/kg were administered to mice and doses of 70 mg/kg, 200 mg/kg and 600 mg/kg were administered to rats in the initial period of approximately 41 to 52 weeks. The high and middle doses were subsequently adjusted due to tolerability and reduced by 50% in mice and by 50% to 66% in rats to allow for completion of the studies. In the mouse study, statistically significant increases in the incidences of hepatocellular carcinoma and incidences of hepatocellular adenomas or carcinomas combined were observed in treated females. In the rat study, no statistically significant increases in tumor findings were observed in either sex. The relevance of these liver tumor findings in mice to humans is not known. Because of tolerability of the formulation in these rodent studies, maximum systemic drug exposures achieved at the doses tested were lower than those in humans at the clinical dose (400 mg/day), with animal vs. human AUC ratios being 0.6-fold (mice) and 0.2-to-0.7-fold (rats).

Mutagenesis

Etravirine tested negative in the *in vitro* Ames reverse mutation assay, *in vitro* chromosomal aberration assay in human lymphocyte, and *in vitro* clastogenicity mouse lymphoma assay, tested in the absence and presence of a metabolic activation system. Etravirine did not induce chromosomal damage in the *in vivo* micronucleus test in mice.

Impairment of Fertility

No effects on fertility and early embryonic development were observed when etravirine was tested in rats at maternal doses up to 500 mg/day, resulting in systemic drug exposure up to the recommended human dose (400 mg/day).

14 CLINICAL STUDIES

14.1 Treatment-Experienced Adult Subjects

The clinical efficacy of etravirine is derived from the analyses of 48-week data from 2 ongoing, randomized, double-blinded, placebo-controlled, Phase 3 trials, TMC125-C206 and TMC125-C216 (DUET-1 and DUET-2) in subjects with 1 or more NNRTI resistance-associated substitutions. These trials are identical in design and the results below are pooled data from the two trials.

TMC125-C206 and TMC125-C216 are Phase 3 studies designed to evaluate the safety and antiretroviral activity of etravirine in combination with a background regimen (BR) as compared to placebo in combination with a BR. Eligible subjects were treatment-experienced HIV-1-infected subjects with plasma HIV-1 RNA greater than 5,000 copies/mL while on an antiretroviral regimen for at least 8 weeks. In addition, subjects had 1 or more NNRTI resistance-associated substitutions at screening or from prior genotypic analysis, and 3 or more of the following primary PI substitutions at screening: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M. Randomization was stratified by the intended use of ENF in the BR, previous use of darunavir/ritonavir, and screening viral load. Virologic response was defined as HIV-1 RNA less than 50 copies/mL at Week 48.

All study subjects received darunavir/ritonavir as part of their BR, and at least 2 other investigator-selected antiretroviral drugs (N[t]RTIs with or without ENF). Of etravirine-treated subjects, 25.5% used ENF for the first time (*de novo*) and 20.0% re-used ENF. Of placebo-treated subjects, 26.5% used *de novo* ENF and 20.4% re-used ENF.

In the pooled analysis for TMC125-C206 and TMC125-C216, demographics and baseline characteristics were balanced between the etravirine arm and the placebo arm (Table 13). Table 13 displays selected demographic and baseline disease characteristics of the subjects in the etravirine and placebo arms.

Table 13: Demographic and Baseline Disease Characteristics of Subjects (Pooled Analysis TMC125-C206 and TMC125-C216)—

	Etravirine + BR N=599	Placebo + BR N=604
Demographic characteristics		
Median age, years (range)	46 (18 to 77)	45 (18 to 72)
Sex		
Male	90.0%	88.6%
Female	10.0%	11.4%
Race		
White	70.1%	69.8%
Black	13.2%	13.0%
Hispanic	11.3%	12.2%
Asian	1.3%	0.6%
Other	4.1%	4.5%
Baseline disease characteristics		
Median		

baseline plasma HIV-1 RNA (range), log ₁₀ copies/mL	4.8 (2.7 to 6.8)	4.8 (2.2 to 6.5)
Percentage of subjects with baseline viral load:		
< 30,000 copies/mL	27.5%	28.8%
≥ 30,000 copies/mL	34.4%	35.3%
and < 100,000 copies/mL	38.1%	35.9%
≥ 100,000 copies/mL		
Median baseline CD4+ cell count (range), cells/mm ³	99 (1 to 789)	109 (0 to 912)
Percentage of subjects with baseline CD4+ cell count:		
< 50 cells/mm ³	35.6%	34.7%
≥ 50 cells/mm ³	34.8%	34.5%
and < 200 cells/mm ³	29.6%	30.8%
≥ 200 cells/mm ³		
Median (range) number of primary PI substitutions*	4 (0 to 7)	4 (0 to 8)
Percentage of subjects with previous use of NNRTIs:		
0	8.2%	7.9%
1	46.9%	46.7%
	44.9%	45.4%

> 1		
Percentage of subjects with previous use of the following NNRTIs:		
Efavirenz	70.3%	72.5%
Nevirapine	57.1%	58.6%
Delavirdine	13.7%	12.6%
Median (range) number of NNRTI RASs †	2 (0 to 8)	2 (0 to 7)
Median fold change of the virus for the following NNRTIs:		
Delavirdine	27.3	26.1
Efavirenz	63.9	45.4
Etravirine	1.6	1.5
Nevirapine	74.3	74.0
Percentage of subjects with previous use of a fusion inhibitor	39.6%	42.2%
Percentage of subjects with a Phenotypic Sensitivity Score (PSS) for the background therapy ‡ of:		
0	17.0%	16.2%
1	36.5%	38.7%
2	26.9%	27.8%
≥ 3	19.7%	17.3%
RASs = Resistance-Associated Substitutions, BR=background regimen, FC = fold change in EC		
50		
* IAS-USA primary PI		

substitutions [August/September 2007]: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, L76V, V82A/F/L/S/T, I84V, N88S, L90M

† Tibotec NNRTI RASs [June 2008]: A98G, V90I, L100I, K101E/H/P/Q, K103H/N/S/T, V106A/M/I, V108I, E138A/G/K/Q, V179D/E/F/G/I/T, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P255H, F227C/L, M230I/L, P236L, K238N/T, Y318F

‡ The PSS was calculated for the background therapy (as determined on Day 7). Percentages are based on the number of subjects with available phenotype data. For fusion inhibitors (enfuvirtide), subjects were considered resistant if the drug was used in previous therapy up to baseline. Etravirine is not included in this calculation.

Efficacy at Week 48 for subjects in the etravirine and placebo arms for the pooled TMC125-C206 and TMC125-C216 study populations are shown in Table 14.

Table 14: Treatment Outcomes at Week 48 (Pooled Analysis TMC125-C206 and TMC125-C216)

	Etravirine + BR N=599	Placebo + BR N=604
Virologic responders at Week 48 Viral Load < 50 HIV-1 RNA copies/mL	359 (60%)	232 (38%)
Virologic failures at Week 48 Viral Load ≥ 50 HIV-1 RNA copies/mL	123 (21%)	201 (33%)
Death	11 (2%)	19 (3%)
Discontinuations before Week		

48:		
due to virologic failures	58 (10%)	110 (18%)
due to adverse events	31 (5%)	14 (2%)
due to other reasons	17 (3%)	28 (5%)
BR=background regimen		

At Week 48, 70.8% of etravirine-treated subjects achieved HIV-1 RNA less than 400 copies/mL as compared to 46.4% of placebo-treated subjects. The mean decrease in plasma HIV-1 RNA from baseline to Week 48 was $-2.23 \log_{10}$ copies/mL for etravirine-treated subjects and $-1.46 \log_{10}$ copies/mL for placebo-treated subjects. The mean CD4+ cell count increase from baseline for etravirine-treated subjects was 96 cells/mm³ and 68 cells/mm³ for placebo-treated subjects.

Of the study population who either re-used or did not use ENF, 57.4% of etravirine-treated subjects and 31.7% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies/mL. Of the study population using ENF *de novo*, 67.3% of etravirine-treated subjects and 57.2% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies/mL.

Treatment-emergent CDC category C events occurred in 4% of etravirine-treated subjects and 8.4% of placebo-treated subjects.

Study TMC125-C227 was a randomized, exploratory, active-controlled, open-label, Phase 2b trial. Eligible subjects were treatment-experienced, PI-naïve HIV-1-infected subjects with genotypic evidence of NNRTI resistance at screening or from prior genotypic analysis. The virologic response was evaluated in 116 subjects who were randomized to etravirine (59 subjects) or an investigator-selected PI (57 subjects), each given with 2 investigator-selected N(t)RTIs. Etravirine-treated subjects had lower antiviral responses associated with reduced susceptibility to the N(t)RTIs and to etravirine as compared to the control PI-treated subjects.

14.2 Treatment-Experienced Pediatric Subjects (2 Years to Less Than 18 Years of Age)

The efficacy of etravirine for treatment-experienced pediatric subjects is based on two Phase 2 trials, TMC125-C213 and TMC125-C234/IMPAACT P1090.

Pediatric Subjects (6 Years to Less Than 18 Years of Age [TMC125-C213])

TMC125-C213, a single-arm, Phase 2 trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of etravirine enrolled 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 2 years to less than 18 years of age and weighing at least 10 kg. Subjects eligible for this trial were on an antiretroviral regimen with confirmed plasma HIV-1 RNA of at least 500 copies/mL and viral susceptibility to etravirine at screening.

The median baseline plasma HIV-1 RNA was $3.9 \log_{10}$ copies/mL, and the median baseline CD4+ cell count was 385×10^6 cells/mm³.

At Week 24, 52% of subjects had HIV-1 RNA less than 50 copies per mL. The proportion

of subjects with HIV-1 RNA less than 400 copies/mL was 67%. The mean CD4+ cell count increase from baseline was 112×10^6 cells/mm³.

Pediatric Subjects (2 Years to Less Than 6 Years of Age [TMC125-C234/IMPAACT P1090])

TMC125-C234/IMPAACT P1090 is a Phase 1/2 trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of etravirine in 20 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 2 years to less than 6 years of age. The study enrolled subjects who had virologic failure on an antiretroviral treatment regimen after at least 8 weeks of treatment, or who had interrupted treatment for at least 4 weeks. Enrolled subjects had a history of virologic failure while on an antiretroviral regimen, with a confirmed HIV-1 RNA plasma viral load greater than 1,000 copies/mL and with no evidence of phenotypic resistance to etravirine at screening.

The median baseline plasma HIV-1 RNA was 4.4 log₁₀ copies/mL, the median baseline CD4+ cell count was 817.5×10^6 cells/mm³, and the median baseline CD4+ percentage was 28%.

Virologic response, defined as achieving plasma viral load less than 400 HIV-1 RNA copies/mL, was evaluated.

Study treatment included etravirine plus an optimized background regimen of antiretroviral drugs. In addition to etravirine, all 20 subjects received a ritonavir-boosted protease inhibitor in combination with 1 or 2 NRTIs (n = 14) and/or in combination with an integrase inhibitor (n = 7).

At the time of the Week 24 analysis, seventeen subjects had completed at least 24 weeks of treatment or discontinued earlier. At Week 24, the proportion of subjects with less than 400 HIV-1 RNA copies/mL was 88% (15/17), and the proportion of subjects with less than 50 HIV-1 RNA copies/mL was 50% (7/14), for those with available data. The median change in plasma HIV-1 RNA from baseline to Week 24 was -2.14 log₁₀ copies/mL. The median CD4+ cell count increase and the median CD4+ percentage increase from baseline was 298×10^6 cells/mm³ and 5%, respectively.

16 HOW SUPPLIED/STORAGE AND HANDLING

Etravirine Tablets, USP **100 mg** are supplied as white to off-white, oval shaped, uncoated tablets debossed with "AC75" on one side and plain on the other side.

They are available as follows:

Bottles of 120 with child-resistant closure: NDC 42291-473-12

Each bottle contains 3 desiccant pouches.

Etravirine Tablets, USP **200 mg** are supplied as white to off-white, oval shaped, uncoated tablets debossed with "AC76" on one side and plain on the other side.

They are available as follows:

Bottles of 60 with child-resistant closure: NDC 42291-474-60

Each bottle contains 3 desiccant pouches.

Store etravirine tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15°

to 30°C (59° to 86°F) [see USP controlled room temperature]. Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.

For more information, go to www.avkare.com or call 1-855-361-3993.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Administration

Advise patients to take etravirine tablets following a meal twice a day on a regular dosing schedule, as missed doses can result in development of resistance. The type of food does not affect the exposure to etravirine. Inform patients not to take more or less than the prescribed dose of etravirine or discontinue therapy with etravirine without consulting their physician. Etravirine must always be used in combination with other antiretroviral drugs [see *Dosage and Administration (2.4)*].

Advise patients to swallow the etravirine tablet(s) whole with a liquid such as water. Instruct patients not to chew the tablets. Patients who are unable to swallow the etravirine tablet(s) whole may disperse the tablet(s) in water. The patient should be instructed to do the following:

- place the tablet(s) in 5 mL (1 teaspoon) of water, or at least enough liquid to cover the medication,
- stir well until the water looks milky,
- add approximately 15 mL (1 tablespoon) of liquid. Water may be used, but orange juice or milk may improve taste. Patients should not place the tablets in orange juice or milk without first adding water. The use of warm (temperature greater than 104°F [greater than 40°C]) or carbonated beverages should be avoided.
- drink the mixture immediately,
- rinse the glass several times with orange juice, milk or water and completely swallow the rinse each time to make sure the patient takes the entire dose.

Severe Skin Reactions

Inform patients that severe and potentially life-threatening rash has been reported with etravirine. Rash has been reported most commonly in the first 6 weeks of therapy. Advise patients to immediately contact their healthcare provider if they develop rash. Instruct patients to immediately stop taking etravirine and seek medical attention if they develop a rash associated with any of the following symptoms as it may be a sign of a more serious reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis or severe hypersensitivity: fever, generally ill feeling, extreme tiredness, muscle or joint aches, blisters, oral lesions, eye inflammation, facial swelling, swelling of the eyes, lips, mouth, breathing difficulty, and/or signs and symptoms of liver problems (e.g., yellowing of your skin or whites of your eyes, dark or tea colored urine, pale colored stools/bowel movements, nausea, vomiting, loss of appetite, or pain, aching or sensitivity on your right side below your ribs). Patients should understand that if severe rash occurs, they will be closely monitored, laboratory tests will be ordered and appropriate therapy will be initiated [see *Warnings and Precautions (5.1)*].

Drug Interactions

Etravirine may interact with many drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort [see *Warnings and Precautions (5.2)*].

Immune Reconstitution Syndrome

Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started [see *Warnings and Precautions (5.3)*].

Fat Redistribution

Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including etravirine, and that the cause and long-term health effects of these conditions are not known at this time [see *Warnings and Precautions (5.4)*].

Pregnancy Registry

Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to etravirine [see *Use in Specific Populations (8.1)*].

Lactation

Instruct mothers with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in breast milk [see *Use in Specific Populations (8.2)*].

All brands listed are trademark of their respective owner.

Manufactured for:

AvKARE

Pulaski, TN 38478

Manufactured by:

Amneal Pharmaceuticals of New York, LLC

Brookhaven, NY 11719

Mfg. Rev. 12-2025-01 AV 12/25

PATIENT INFORMATION

Etravirine (e" tra vir' een) Tablets

Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with etravirine tablets. For more information, see the section "What should I tell my healthcare provider before taking etravirine tablets?"

What are etravirine tablets?

Etravirine tablet is a prescription medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection in combination with other HIV-1 medicines, in adults and children 6 years of age and older who have taken HIV-1 medicines in the past.

HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

Etravirine tablets are not recommended for use in children less than 2 years of age.

What should I tell my healthcare provider before taking etravirine tablets?

Before taking etravirine tablets tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems, including hepatitis B or C.
- are pregnant or plan to become pregnant. Tell your healthcare provider if you become pregnant during treatment with etravirine tablets.

Pregnancy Registry: There is a pregnancy registry for people who take etravirine tablets during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.

- are breastfeeding or plan to breastfeed. Do not breastfeed if you take etravirine tablets.
 - You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.
 - Etravirine can pass to your baby in your breast milk.
 - Talk with your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Some medicines may interact with etravirine tablets. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

- You can ask your healthcare provider or pharmacist for a list of medicines that interact with etravirine tablets.
- **Do not start a new medicine without telling your healthcare provider.** Your healthcare provider can tell you if it is safe to take etravirine tablets with other medicines.

How should I take etravirine tablets?

- **Stay under the care of your healthcare provider during treatment with etravirine tablets.**
- **Take etravirine tablets every day exactly as prescribed by your healthcare provider.**
- Your healthcare provider will tell you how many etravirine tablets to take and when to take them. Talk to your healthcare provider if you have questions about when to take etravirine tablets.
- Take etravirine tablets 2 times each day.
- If your child takes etravirine tablets, your healthcare provider will prescribe the right dose based on your child's weight.
- **Always take etravirine tablets following a meal.** Do not take etravirine tablets on an empty stomach. Etravirine tablets may not work as well if you take it on an empty stomach.
- Do not change your dose or stop taking etravirine tablets without first talking with your healthcare provider.
- Swallow etravirine tablets whole, with liquid, such as water. Do not chew the tablet(s).
- If you are unable to swallow etravirine tablets whole, you may take your dose of etravirine tablets as follows:

Step 1: Measure approximately 5 mL (1 teaspoon) of water and pour into a cup.

Step 2: Place the tablets in the cup containing 5 mL of water. If needed, add more water to cover the tablets. **Do not put the tablets in other liquids.**

Step 3: Stir well until the water looks milky.

Step 4: Add a small amount (approximately 15 mL or 1 tablespoon) of liquid. Water may be used but adding orange juice or milk rather than water may make it easier to take. Do not use warm (temperature more than 104°F or 40°C) or carbonated beverages.

Step 5: Drink the mixture right away.

Step 6: Add more orange juice, milk, or water to the cup to rinse the cup several times and completely swallow each time to make sure you take your entire dose of etravirine tablets.

- It is important that you do not miss or skip doses of etravirine tablets during treatment.
- When your supply of etravirine tablets starts to run low, get more from your healthcare provider or pharmacy. It is important not to run out of etravirine tablets. The amount of HIV in your blood may increase if the medicine is stopped even for a short time.
- If you take too much etravirine tablets, call your healthcare provider or go to the nearest emergency room right away.

What are the possible side effects of etravirine tablets?

Etravirine tablets can cause serious side effects including:

- **Severe skin rash and allergic reactions.** Skin rash is a common side effect of etravirine tablets. The risk of getting a skin rash is higher in females. Rarely, rash can be severe and may lead to death. Severe skin rash with blisters or peeling skin, including the area around the mouth or eyes, may happen more frequently in children less than 18 years of age who take etravirine tablets in combination with other HIV-1 medicines than in adults. Call your healthcare provider right away if a rash develops; severe cases may need to be treated in a hospital.

If you get a rash with any of the following symptoms, stop taking etravirine tablets and call your healthcare provider or get medical help right away:

-
- | | | |
|-------------------------|-----------------------------------|--|
| ◦ fever | ◦ muscle or joint aches | ◦ redness or swelling of the eyes |
| ◦ generally ill feeling | ◦ blisters or sores in mouth | ◦ swelling of the mouth, lips, or face |
| ◦ extreme tiredness | ◦ blisters or peeling of the skin | ◦ problems breathing |
-

Sometimes allergic reactions can affect body organs, such as your liver. Call your healthcare provider right away if you have any of the following signs or symptoms of liver problems:

-
- yellowing of your skin or whites of your eyes
 - dark or tea colored urine
 - pale colored stools (bowel movements)
 - nausea or vomiting
 - loss of appetite
 - pain, aching, or tenderness on the right side of your stomach area
-

- **Changes in your immune system (Immune Reconstitution Syndrome)** can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Call your healthcare provider right away if you start having any new symptoms after starting your HIV-1 medicines.
- **Changes in body fat** can happen in people taking HIV-1 medicines. These changes may include an increased amount of fat in the upper back and neck (“buffalo hump”), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these problems are not known.

The most common side effects of etravirine tablets in adults include rash as well as numbness, tingling or pain in the hands or feet.

The most common side effects of etravirine tablets in children include rash and diarrhea.

These are not all the possible side effects of etravirine tablets.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store etravirine tablets?

- Store etravirine tablets at room temperature between 68° to 77°F (20° to 25°C).
- Keep etravirine tablets in the original bottle. Etravirine tablets come in a child-resistant package.
- Keep the bottle tightly closed to protect etravirine tablets from moisture.
- The etravirine tablets bottle contains a desiccant packet to help keep your medicine dry (protect it from moisture). The bottle of 25 mg tablets contains 2 desiccant packets. The bottles of 100 mg and 200 mg tablets contain 3 desiccant packets. Keep the desiccant packets in the bottle. **Do not eat the desiccant packets.**

Keep etravirine tablets and all medicines out of the reach of children.

General information about the safe and effective use of etravirine tablets

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use etravirine tablets for a condition for which it was not prescribed. Do not give etravirine tablets to other people, even if they have the same

symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about etravirine tablets that is written for health professionals.

What are the ingredients in etravirine tablets?

Active ingredient: etravirine.

25 mg, 100 mg and 200 mg tablets contain the following inactive ingredients: croscarmellose sodium, crospovidone (type A), colloidal silicon dioxide, hypromellose, low-substituted hydroxy propyl cellulose, magnesium stearate and microcrystalline cellulose.

Additional pediatric use information is approved for Janssen Products, LP's INTELENCE[®] (etravirine) tablets. However, due to Janssen Products, LP's marketing exclusivity rights, this drug product is not labeled with that pediatric information.

For more information, go to www.avkare.com or call toll-free 1-855-361-3993.

This Patient Information has been approved by the U.S. Food and Drug Administration.

All brands listed are trademark of their respective owner.

Manufactured for:

AvKARE

Pulaski, TN 38478

Manufactured by:

Amneal Pharmaceuticals of New York, LLC

Brookhaven, NY 11719

Mfg. Rev. 03-2022-00 AV 03/22

NDC 42291-473-12

Etravirine Tablets, USP

100 mg

ALERT: Find out about medicines that should NOT be taken with Etravirine Tablets from your healthcare provider.



Rx only
120 Tablets



Each tablet contains:
Etravirine, USP.....100 mg

USUAL DOSAGE: See package Insert for full Prescribing Information.

This package is child-resistant. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Store in the original bottle and protect from moisture.

Keep this and all medications out of the reach of children.

Manufactured for: AvKARE, Pulaski, TN 38478
Manufactured by: Amneal Pharmaceuticals of NY, LLC
Brookhaven, NY 11719
Mfg. Rev. 12-2025-01 AV 12/25



Non-Varnish Area
(For Lot And Exp. Date)
(22 X 57 mm)

NDC 42291-474-60

Etravirine Tablets, USP

200 mg

ALERT: Find out about medicines that should NOT be taken with Etravirine Tablets from your healthcare provider.



Rx only
60 Tablets

Each tablet contains:

Etravirine, USP.....200 mg

USUAL DOSAGE: See package insert for full Prescribing Information.

This package is child-resistant. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP controlled room temperature]. Store in the original bottle and protect from moisture.

Keep this and all medications out of the reach of children.

Manufactured for: AvKARE, Pulaski, TN 38478

Manufactured by: Amneal Pharmaceuticals of NY, LLC
Brookhaven, NY 11719

Mfg. Rev. 12-2025-01 AV 12/25



Non-Varnish Area
(For Lot And Exp. Date)
(22 X 57 mm)

ETRAVIRINE

etravirine tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:42291-473
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ETRAVIRINE (UNII: 0C50HW4FO1) (ETRAVIRINE - UNII:0C50HW4FO1)	ETRAVIRINE	100 mg

Inactive Ingredients

Ingredient Name	Strength
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
CROSPVIDONE (UNII: 2S7830E561)	
HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)	
LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	

Product Characteristics

Color	white (white to off-white)	Score	no score
Shape	OVAL	Size	18mm
Flavor		Imprint Code	AC75
Contains			

Packaging

		Marketing Start	Marketing End
--	--	------------------------	----------------------

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42291-473-12	120 in 1 BOTTLE; Type 0: Not a Combination Product	10/04/2022	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA214196	10/04/2022	

ETRAVIRINE				
etravirine tablet				
Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:42291-474	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
	Ingredient Name	Basis of Strength	Strength	
	ETRAVIRINE (UNII: 0C50HW4FO1) (ETRAVIRINE - UNII:0C50HW4FO1)	ETRAVIRINE	200 mg	
Inactive Ingredients				
	Ingredient Name	Strength		
	CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)			
	CROSPVIDONE (UNII: 2S7830E561)			
	HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)			
	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 2165RE0K14)			
	MAGNESIUM STEARATE (UNII: 70097M6I30)			
	MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)			
	SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			
Product Characteristics				
Color	white (white to off-white)	Score	no score	
Shape	OVAL	Size	22mm	
Flavor		Imprint Code	AC76	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42291-474-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	10/04/2022	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA214196	10/04/2022	

Labeler - AvKARE (796560394)

Revised: 1/2026

AvKARE